|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2006-6-14
|
|
pubmed:abstractText |
We present the long-term results of 18 chemotherapy relapsed indolent (N = 12) or transformed (N = 6) NHL patients of a phase II anti-CD20 (131)I-tositumomab (Bexxar) therapy study. The biphasic therapy included two injections of 450 mg unlabelled antibody combined with (131)I-tositumomab once as dosimetric and once as therapeutic activity delivering 75 or 65 cGy whole-body radiation dose to patients with normal or reduced platelet counts, respectively. Two patients were not treated due to disease progression during dosimetry. The overall response rate was 81% in the 16 patients treated, including 50% CR/CRu and 31% PR. Median progression free survival of the 16 patients was 22.5 months. Median overall survival has not been reached after a median observation of 48 months. Median PFS of complete responders (CR/CRu) has not been reached and will be greater than 51 months. Short-term side effects were mainly haematological and transient. Among the relevant long-term side effects, one patient previously treated with CHOP chemotherapy died from secondary myelodysplasia. Four patients developed HAMA. In conclusion, (131)I-tositumomab RIT demonstrated durable responses especially in those patients who achieved a complete response. Six of eight CR/CRu are ongoing after 46-70 months.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-10561185,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-10715303,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-10942366,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-11579112,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12011122,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12036859,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12149300,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12610191,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12621016,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12663713,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-12738671,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-1351599,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-1423295,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-14976046,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15016644,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15084620,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15159414,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15453924,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15471849,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15494430,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15613695,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15681517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15689582,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15731177,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-15869453,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-16110029,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-16186600,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-1708835,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-3531422,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-6086763,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-7687326,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-8648385,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-8949411,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-9012472,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-9704735,
http://linkedlifedata.com/resource/pubmed/commentcorrection/16685263-9708566
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0007-0920
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
19
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1770-6
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16685263-Adult,
pubmed-meshheading:16685263-Aged,
pubmed-meshheading:16685263-Antibodies, Monoclonal,
pubmed-meshheading:16685263-Antineoplastic Agents,
pubmed-meshheading:16685263-Disease-Free Survival,
pubmed-meshheading:16685263-Female,
pubmed-meshheading:16685263-Humans,
pubmed-meshheading:16685263-Lymphoma, Non-Hodgkin,
pubmed-meshheading:16685263-Male,
pubmed-meshheading:16685263-Middle Aged,
pubmed-meshheading:16685263-Neoplasm Recurrence, Local,
pubmed-meshheading:16685263-Survival Analysis,
pubmed-meshheading:16685263-Survival Rate,
pubmed-meshheading:16685263-Time,
pubmed-meshheading:16685263-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Long-term complete responses after 131I-tositumomab therapy for relapsed or refractory indolent non-Hodgkin's lymphoma.
|
|
pubmed:affiliation |
Service of Nuclear Medicine, University Hospital of Lausanne, Switzerland. Franz.Buchegger@chuv.ch
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase II
|
